STAFFORD, Texas, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on corporate events. The Company's 2024 events to date are listed below: Feb 29 - Mar 1, 2024 – GBG Annual Scientific Meeting (German clinical network conference)Jun 1 - 4, 202 ...

亏损情况 - 2023年和2022年12月31日结束的年度净亏损分别约为890万美元和780万美元，2024年和2023年9月30日结束的九个月净亏损分别为770万美元和610万美元[37] 费用变化 - 2024年9月30日结束的三个月研发费用较2023年同期增加133873美元，涨幅6%，主要因临床费用增加[40] - 2024年9月30日结束的三个月管理费用较2023年同期增加92253美元，涨幅27%，主要因财务费用增加[41] - 2024年9月30日结束的九个月研发费用较2023年同期增加1428785美元，涨幅27%，主要因临床费用增加[41] - 2024年9月30日结束的九个月管理费用较2023年同期增加7038美元，涨幅1%[42] 现金情况 - 2024年9月30日和2023年12月31日现金分别为5822367美元和6989424美元[44] 经营活动现金净流出 - 2024年9月30日结束的九个月经营活动现金净流出较2023年同期增加[46] 股票收益 - 2024年1月1日至9月30日公司出售普通股总收益1941424美元，净收益1747282美元[47] - 2024年6月13日公司完成私募发行普通股净收益2499998美元[48] 项目扩展计划 - 公司正在进行Flamingo - 01项目扩展到欧洲计划全球开设150个站点[36]

临床试验进展 - 公司正处于临床三期试验阶段，正在评估GLSI-100免疫治疗预防乳腺癌复发的疗效[57] 财务状况 - 公司尚未产生任何收入，持续亏损，预计未来将继续大幅亏损[58][59] - 公司现金余额为722.49万美元，预计现有现金资源可维持公司未来12个月的计划运营[65] - 公司通过ATM协议和私募发行股票筹集了约4.26百万美元的资金[68][69][70] 研发投入 - 研发费用较上年同期增加67%，主要是由于临床和制造费用的增加[60] 会计政策变更 - 公司采用了FASB 2016-13号会计准则，该准则对公司财务报表和相关披露没有重大影响[74] - 公司将利用JOBS法案的豁免条款,延迟采用新的会计准则[76][77][78]

STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 ...

STAFFORD, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the following update of the expansion of clinical sites into Spain. As previously announced, the Company has partnered with GEICAM, the largest academic breast cancer research network in Spain, where 38 ...

STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list o ...

STAFFORD, Texas, June 26, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it is set to join the Russell 2000 and Russell 3000 Indexes at the conclusion of the Russell indexes annual reconstitution, effective after the US markets open on July 1, 2024, according to a list ...

STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (NASDAQ:GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase price ...

STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that it has entered into a securities purchase agreement with its Chief Executive Officer, Snehal Patel, for the purchase and sale of 174,825 shares of its common stock at a purchase pric ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to COMMISSION FILE NUMBER 001-39555 GREENWICH LIFESCIENCES, INC. (Exact Name of registrant as specified in its charter) Delaware 20-5473709 (State or other jurisdiction (I.R ...